MAP2K7 and neoplasm: The COMBI-d and COMBI-v trials showed a significant improvement in OS and PFS in patients treated with dabrafenib plus trametinib (MEK inhibitor) when patients started at less than 3 tumor sites (n = 282) versus more than or equal to 3 tumor sites (n = 269) [25].